HOME >> BIOLOGY >> NEWS
Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases

Berkeley -- An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

The mouse study, reported in the Sept. 21 issue of the journal Proceedings of the National Academy of Sciences by scientists at Cerus Corp. in Concord, Calif., employs a genetically engineered listeria bacteria based on a strain created by coauthor and University of California, Berkeley, microbiologist Daniel Portnoy. Buoyed by the success of the new cancer vaccine, Cerus scientists now are aiming for human trials.

Cerus ultimately hopes to use the genetically engineered listeria vaccine to target cancers such as pancreatic and ovarian cancer, and possibly leukemia and various solid tumors.

The listeria bacteria are uniquely effective vehicles for a cancer vaccine, Portnoy said, because the bacteria incite a strong "innate" response from the immune system and at the same time sneak cancer antigens into cells to optimally stimulate a potent "acquired" immune response. Together, these two independent arms of the human immune system can deliver a one-two punch to cancer cells. Antigens are like a red flag to a bull -- they draw an attack from cells of the immune system -- but the strength of the immune response depends on how the flag is waved.

"This immune therapy uses bacteria that induce both inflammation and an immune response to specific tumor antigens," which together hit the tumor with generalized antitumor chemicals, such as interferon and tumor necrosis factor, as well as activated T-cells that attack and kill the tumor, Portnoy said. "Listeria is the best bug so far to induce that response. With listeria, innate and acquired immunity work in concert."

Portnoy, a professor of molecular and cell biology and of public health and a member of UC Berkeley's Health Sciences Initiative, identified the genes in listeria that make
'"/>

Contact: Robert Sanders
rls@pa.urel.berkeley.edu
510-643-6998
University of California - Berkeley
29-Sep-2004


Page: 1 2 3 4 5

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Cancer gene MYC emerging as key research target
4. Cancer patient, heal thyself
5. USC researcher named General Motors Cancer Research Scholar
6. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
7. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
8. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
9. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
10. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
11. Dana-Farber launches Center for Applied Cancer Science

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2020)... , ... March 13, 2020 , ... ... with Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics ... and medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and ...
(Date:3/11/2020)... ... March 11, 2020 , ... ... sensing, today announced smart human body temperature infrared touch-free monitoring product family, a ... meter WxS x800-IRTM, supporting flexible wireless uplink for cloud connectivity such as NB-IoT, ...
(Date:3/9/2020)... DALLAS (PRWEB) , ... March ... ... by enterprises witnessed a steep growth rate of 64% last year, as ... to new research from Everest Group. Unfortunately, only 13% of all transformation ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader of in ... ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing format used ... ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. The clearances ...
(Date:3/3/2020)... ... March 03, 2020 , ... ... biotech and medical device industries, was recognized by INC. 5,000 on an annual ... lists to note industry leaders greatly impacting their spheres of influence and experiencing ...
(Date:2/21/2020)... ... 2020 , ... In a free session on Tuesday, March 10, ... Lisa Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, ... to support patients, sites and sponsors. , When planning a rare disease clinical trial, ...
(Date:2/19/2020)... ... February 18, 2020 , ... Shoreline Biome, a ... strain level, recently unveiled a novel DNA isolation product. , Shoreline Rapid Prep ... high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB from ...
Breaking Biology Technology:
Cached News: